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Identification of disease 
comorbidity through hidden 
molecular mechanisms
Younhee Ko1, Minah Cho2, Jin-Sung Lee1 & Jaebum Kim2
Despite multiple diseases co-occur, their underlying common molecular mechanisms remain elusive. 
Identification of comorbid diseases by considering the interactions between molecular components is a 
key to understand the underlying disease mechanisms. Here, we developed a novel approach utilizing 
both common disease-causing genes and underlying molecular pathways to identify comorbid diseases. 
Our approach enables the analysis of common pathologies shared by comorbid diseases through 
molecular interaction networks. We found that the integration of direct genetic sharing and indirect 
high-level molecular associations revealed significantly strong consistency with known comorbid 
diseases. In addition, neoplasm-related diseases showed high comorbidity patterns within themselves 
as well as with other diseases, indicating severe complications. This study demonstrated that molecular 
pathway information could be used to discover disease comorbidity and hidden biological mechanism 
to understand pathogenesis and provide new insight on disease pathology.
The core in comorbidity research lies in the elucidation of pathological properties of diseases and their coordi-
nated activities at molecular level. In recent years, remarkable advances in the understanding of human disease 
mechanisms have provided increasing evidence that most complex diseases are caused by the breakdown of con-
certed activities of many genes involved in common or related cellular processes1–3. The coexistence of two or 
more diseases in an individual raises the question about their underlying common etiological pathways. The 
study of comorbidity patterns of diseases could help us understand the underlying molecular disease mechanisms 
and identify potential novel disease-causing genes or associated biological pathways4.
Several studies have investigated comorbidity patterns of diseases5–10 by considering several biological factors 
relevant to existing comorbidities. The etiology of comorbid diseases occurring in an individual can be explained 
by two mechanisms. First, directly shared biological factors such as common disease genes can cause comor-
bid diseases. Second, comorbid diseases can occur together since they are co-regulated by high-level biological 
mechanisms such as the same cellular pathways. Most existing studies have focused on the first mechanism. For 
example, direct overlap of disease-associated genes has been identified as a one of critical factors to explain the 
comorbid diseases11. The number of direct protein-protein interactions (PPIs) between causative proteins of two 
diseases has also been considered to explain the hidden comorbidity patterns7,12,13. Recently, symptom similarity 
has been used to explain the unexpected association among diseases, disease etiology, and drug design9. However, 
comorbid diseases are more likely to co-occur because disease-associated genes are indirectly co-regulated by 
underlying common biological mechanisms4,8,14. In order to study the pathology of comorbid diseases, both 
direct sharing of disease-associated genes or PPIs and indirect common mechanisms should be considered.
In this study, we combined functional relations between protein coding genes and biological modules asso-
ciated with them to investigate the etiology of unexplained comorbidity and to elucidate the molecular origins 
or underlying mechanisms of such comorbid diseases. First, we compiled large-scale gene-disease associ-
ations by integrating four well-known disease databases. We then developed a method to identify comorbid 
diseases through functional association networks. For clinical validation, the US Medicare database15 was 
used. These analyses discovered the associated disease mechanisms underlying comorbid diseases and highly 
co-emerged clinical disease categories. We used biological pathways interleaved within indirect relations between 
disease-associated genes to explore novel comorbidity patterns in a systematic way where those genes were linked 
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at the higher molecular network-level. Integration of disease genes and molecular interactions under functional 
networks enabled us to investigate unknown co-occurred disease pairs and their pathobiological properties.
Results
Integration of disease databases and extraction of disease-gene associations. To cover exten-
sive disease-gene associations, four well-known disease databases were integrated (see Methods), which dramat-
ically increased disease coverage (Fig. 1A). Since different disease databases were collected based on different 
biological evidences, coverages of these databases were very different from each other. Our integrated database 
covered 897 diseases (increase of 17.56% compared with previous study12) overlapped with Medicare data. Most 
(79.62%) genes were also covered by STRING network16 used for network-based comorbidity inference (Fig. 1B).
Identification of comorbid diseases. To identify comorbidity patterns of diseases, two quantities (direct 
sharing of disease-associated genes and the commonality of protein-protein interactions (PPIs) between candi-
date comorbid diseases (Fig. 1C)) have been studied7,11,12,15,17. These studies have shown some degree of corre-
lation with the actual comorbidity patterns of diseases obtained from clinical data. However, comorbid diseases 
co-occur not only because they share genes or protein interactions, but also because their pathobiological prop-
erties involve a whole cascade of common perturbed cellular mechanisms. Therefore, only considering these two 
quantities would not be enough to explain comorbidity patterns and their pathobiological properties.
To address this issue, we developed a new approach by considering high-level molecular associations such as 
biological pathways in addition to the two traditional quantities (Fig. 1C). Recently, EnrichNet (network-based 
gene set enrichment analysis) has been introduced for a new gene set enrichment analysis by considering a gene 
interaction network18. We adapted similar ideas of EnrichNet to infer the degree of comorbidity between two 
diseases that reflect functional closeness among a group of disease-associated genes as well as associated bio-
logical mechanisms. Specifically, given a set of genes and a gene interaction network, the level of reachability 
(called the XD score) from one gene set to the other gene set could be quantified by random walk with restart 
algorithm (Methods). Although different diseases can co-occur due to various reasons including common symp-
toms, shared molecular mechanisms, shared genes, or drug effects, recent comorbidity studies are only applicable 
for disease pairs that directly share molecular components (e.g. common disease genes or common PPIs). This 
may lead to the missing of a large number of meaningful comorbidity patterns, which can result in incomplete 
Figure 1. Statistics of four integrated disease databases (i.e., OMIM, DO, HPO, and GAD) and the overall 
schema of three representative quantities to identify disease comorbidity. (A) Disease overlap among four 
disease databases. The number in parentheses represents the total number of genes in each database. (B) Disease 
gene coverage of the integrated disease database in comparison with STRING network. The x-axis represents 
the proportion of overlap between associated genes of a disease and all genes in the STRING network. The 
y-axis indicates the fraction of diseases. The fraction of diseases (more than 80% of disease genes are covered by 
STRING) is over 95%. (C) Two different strategies to represent the degree of comorbidity between diseases A 
and B. “Direct gene overlap” and “Function network structure” are used to consider overlap between associated 
genes of the two diseases and the number of direct as well as indirect interactions between associated genes of 
the two diseases in a function network, respectively. The “Function network structure” strategy to explain the 
disease comorbidity utilizes disease-associated genes as well as the neighborhood genes which are connected 
to the disease-associated genes. In our study, the STRING interaction database has been used to identify the 
functional interactions.
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understanding of pathobiological properties of diseases. Therefore, our approach will be particularly useful to 
identify hidden comorbidity patterns in cases where diseases share no common gene in the same molecular or 
cellular processes.
Evaluation through real patient data. Our results were evaluated with the US Medicare data. We 
explained the etiology of comorbid diseases with their common molecular mechanisms, which is represented 
as the XD score of two diseases. Thus, we calculated the XD scores of all disease pairs, and measured the 
amount of correlation with the following two traditional scores for disease comorbidity: relative risk (RR) and 
phi-correlation (PHI). For each disease pair, both RR and PHI are calculated based on the amount of patients with 
common diseases from the US Medicare data (see Methods)7,12,15,19. Although RR and PHI describe how often 
two diseases actually co-occur in clinical data, both measures have their own intrinsic biases. Therefore, we used 
both scores to quantify the comorbidity. To determine the effectiveness of our approach, the correlation between 
RR/PHI and the following two quantities or their combinations were compared: (i) the number of common genes 
between two diseases (NG), (ii) the XD score calculated by our approach (Supplementary Table 1).
The overall distribution of the XD score of all disease pairs is shown in Fig. 2 (Fig. 2A, all XD scores; Fig 2B, 
only positive XD scores). To examine the effectiveness of our approach more deeply, we compared the distribution 
of RR and PHI scores of disease pairs extracted from the following different criteria: disease pairs with at least one 
common gene (+ NG), with the positive XD score (+ XD), with both the positive XD score and at least one com-
mon gene (+ XDand + NG), with at least one common gene but without the positive XD score (+ NGnot + XD), 
with the positive XD score but without sharing genes (+ XDnot + NG), and with the negative or zero XD scores 
without common genes (not + XDnot + NG). In this classification, + NG (at least one common gene) and + XD 
(positive XD score) were used as cutoffs because it has been shown that disease pairs having shared genes (e.g. 
NG > 0) have high comorbidity7,8,12,15, and the negative XD score represents that the comorbidity level of two 
disease pairs is low and those set of disease genes have less than average connections (Methods). Among a total 
of 97,665 disease pairs, the number of disease pairs having at least one overlapped disease-associated genes and 
Figure 2. Statistics of comorbidity measures for disease pairs in the US Medicare data. (A) The distribution of 
the log-scaled XD scores. (B) The distribution of the positive XD scores. (C) The numbers of disease pairs chosen by 
different quantities (+ NG: disease pairs having at least one common gene, + XD: disease pairs having the positive 
XD scores). (D) The average and standard errors of RR scores of disease pairs chosen by different quantities. (E) The 
average and standard errors of PHI scores of disease pairs chosen by different quantities. (+ XDand + NG: disease 
pairs having both the positive XD scores and at least one common gene, + NGnot + XD: disease pairs having at least 
one common gene but without the positive XD scores, + XDnot + NG: disease pairs having the positive XD scores 
but without sharing genes, and not + XDnot + NG: disease pairs having the negative or zero XD scores without 
sharing any gene).
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disease pairs having the positive XD score were 6,953 (7%) and 3,759 (4%), respectively. A total of 3,213 (3%) 
disease pairs were common (Fig. 2C). As shown in Fig. 2D and E, disease pairs selected by both the XD score and 
NG (i.e. the +XDand+NG category) revealed the highest comorbidity patterns (i.e., the highest average RR and 
PHI scores) compared to disease pairs in other categories. In addition, disease pairs without +XDor+NG showed 
relatively very low comorbidity patterns. There was no big difference between results using RR and PHI in terms 
of such correlation. This demonstrated that the identification of comorbid diseases could be more accurately 
achieved by both direct molecular evidence represented by NG (the number of shared genes) and systems-level 
factors such as common molecular mechanisms represented by the XD score.
Next, we compared the correlation of the XD scores and NGs obtained from disease pairs of the above six 
categories with RR and PHI scores. In terms of the XD score correlation (the second column in Table 1), the first 
three categories (+ XDand+NG,+ XD,and+NG) had high correlation coefficients both with RR and PHI scores 
with significant p-values from permutation test (see Methods). When neither + XD (positive XD score) nor + 
NG (at least one shared gene) criteria were applied (+ NGnot+ XDand+ XDnot+ NG), the correlation coefficients 
dropped significantly. In terms of the NG value (the third column in Table 1), no significant correlation was found 
in any disease pairs of the five categories.
In conclusion, these results indicate that the NG value or the XD score alone may not be a good indicator 
to explain disease comorbidity. In addition, when both of them were utilized to filter comorbid disease pairs, 
more strong correlation with clinical comorbidity score such as RR/PHI values was observed. This strongly sup-
ports that the combination of the two quantities (the XD score and the NG value) is a better prediction for 
comorbid disease pairs. We repeated the above analyses using the BioGRID network database20, which is smaller 
than the STRING database yet constructed by comprehensive curation, and obtained similar overall patterns 
(Supplementary Fig. 1 and Supplementary Table 2).
Predicted disease network constructed based on shared genetic interaction. A disease network 
that is constructed based on the XD score and NG score can provide the clue for etiology of comorbid dis-
eases through the shared molecular origins such as common genes, shared interactions, or common biological 
pathways, which could not be explained in a comorbidity network constructed based on the RR/PHI values 
from clinical data. Thus, in this study, a disease comorbidity network (Fig. 3) was constructed from disease pairs 
having both the positive XD score and at least one shared gene, including 3,213 (3%) disease pairs out of total 
97,665 ICD-9-CM disease pairs covering a total of 520 ICD-9-CM codes. The negative XD score indicates that 
the association of a disease pair is smaller than an average association level in a functional network. Therefore, 
we only considered disease pairs having the positive XD scores. We classified ICD-9-CM diagnosis codes into 18 
pre-defined disease categories (Supplementary Table 3) and used them to hierarchically organize the predicted 
disease network.
To evaluate the predicted disease association in terms of actual disease comorbidity, 1,000,000 randomized 
disease networks were generated by edge shuffling, and the significance of the number of links across dis-
ease pairs within the same disease category as well as between two different disease categories was examined 
(Supplementary Fig. 2). As shown, 71% of disease categories were classified as significant, while only 39% of 
different disease category pairs were observed to have the significant number of links. This demonstrates the sig-
nificance of predicated disease associations as a good indicator of disease comorbidity patterns.
As shown in Fig. 3A, diseases classified as “Neoplasms”, “Metabolic/immunity disorders”, “Circulatory system”, 
and “Nervous system” had prevalent association patterns with other diseases by representing a large number 
of nodes in the predicted disease network. Diseases belonging to the “Musculoskeletal system” category espe-
cially showed high association with many other diseases (Fig. 3B), indicating that most musculoskeletal diseases 
Criteria for disease 
pairs
XD NG
RR PHI RR PHI
+ XDand+ NG 0.2640 (6.59 × 10−4)
0.1377 
(2.687 × 10−3) − 0.0065 (0.3789) 0.0251 (0.1329)
+ XD 0.2592 (5.20 × 10−4)
0.1432 
(2.29 × 10−3) − 0.0047 (0.2466) 0.0344 (0.0474)
+ NG 0.2407 (3.26 × 10−4)
0.1267 
(1.184 × 10−3) − 0.0023 (0.1753) 0.0360 (0.0338)
+ NGnot+ XD 0.0059 (0.0764) − 0.0209 (0.9999) 0.0096 (0.0892) 0.0288 (0.0357)
+ XDnot+NG 0.0886 (0.0132) 0.0723 (0.0305) NA NA
not+ XDnot+NG − 0.0029 (0.8218) 0.0040 (0.1130) NA NA
ALL 0.1557 (6.67 × 10−6) 0.0759 (0) 0.0013 (0.0521) 0.0254 (0.0016)
Table 1.  Correlation between different measures of disease comorbidity. Numbers represent Pearson’s 
correlation coefficients for XD scores against RR/PHI scores or for NG values against RR/PHI scores calculated 
from different sets of disease pairs constructed by different categories shown at the first column; p-values in 
parenthesis are from permutation tests. +XD: disease pairs having positive XD scores. + NG: disease pairs 
having at least one common gene. +XDand +NG: disease pairs having both positive XD score and at least 
one common gene. + NGnot+ XD: disease pairs having at least one common gene but without having positive 
XD scores. +XDnot+NG: disease pairs having positive XD scores but without having common disease genes. 
not+XDnot+NG: disease pairs having negative XD scores and without having common disease genes.
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often are associated with other diseases by sharing the common biological mechanisms. “Digestive system”, 
“Circulatory system”, and “Skin and subcutaneous tissue” also showed similar patterns.
To quantify the association between disease categories and disease association patterns, we measured the aver-
age number of disease links among different disease categories. This number was then normalized to the number 
of diseases in each disease category. Results for top 10% of disease category pairs having high association are 
shown in Fig. 3C and D. Neoplasm-related diseases had high association pattern within themselves. This could be 
due to the etiological common mechanism of tumors21,22 (Fig. 3C). The next top-ranked highly-associated disease 
categories were mental disorders themselves, metabolic/immunity disorders with circulatory system, metabolic/
immunity disorders with musculoskeletal system, and neoplasms with metabolic/immunity disorders23–26. As 
shown in Fig. 3D, clear associations between neoplasms and other diseases were observed. These high association 
patterns surrounding neoplasms may indicate that the existing complications are associated with cancers and that 
tumor patients might have poor survival and difficult recovery27,28.
Discussion
Despite the lack of clinical data or incomplete understanding of pathology for diseases, our approach success-
fully identified associated disease pairs and the shared pathological mechanisms. Our approach has two main 
Figure 3. Construction of the predicted disease network based on XD score. (A) The top 10% of 
disease pairs having the highest XD score. The color of nodes indicates a disease category based on ICD-9 
classification (Supplementary Table 3). (B) Average degree (number of links with other diseases) of diseases 
in the disease category. The average degree of all diseases in the disease network is 12.543 (marked as a black 
bar). Musculoskeletal system had the highest average degree, indicating that musculoskeletal system related 
diseases often accompany other diseases as complications or are frequently accompanied by other diseases as 
complications. (C) Top-ranked disease category pairs based on the normalized number of links between disease 
categories (including links between different disease category pairs as well as links within one disease category). 
Note that diseases in the neoplasm category have the highest intra-comorbidity patterns. (D) Illustration of 
distinct comorbidity patterns around the neoplasm category. The edge thickness represents the relative degree 
of the XD score between two disease categories.
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advantages: (i) by integrating direct disease-gene overlap and indirect molecular interactions, clinically meaning-
ful comorbid disease pairs can be identified, and (ii) further investigation of shared pathological mechanisms of 
comorbid diseases is possible.
In order to demonstrate the utility of our approach, we predicted associated disease pairs and examined how 
well they are correlated with known comorbid disease pairs. We found that disease pairs with at least one com-
mon gene and the positive XD score have the strongest correlation (Supplementary Fig. 3). In addition, among 
total 97,665 disease pairs used in our analysis, 91,072 pairs did not share any gene (NG = 0), yet more than 40% of 
them shared significant amount of GO terms (Fisher’s exact test with a p-value cutoff 0.05, Supplementary Fig. 3). 
When the XD score was applied to extract the disease pairs for additional filtering, the fraction of disease pairs 
sharing the significant number of GO terms was more increased. This demonstrates that even disease pairs with 
NG = 0 do share common biological processes or molecular functions, and such common mechanisms can be 
explained by the XD score that utilizes propagated genes in a network.
The promising example of our approach is the detailed explanation for common molecular pathology associ-
ated with diseases pairs. For example, “Depressive disorder” (i.e., ICD-9: 311) and “Irritable bowel syndrome” (i.e., 
ICD-9: 564.1) were identified as an associated disease pair (Supplementary Table 1). Although they only share one 
disease-associated gene, they had strong comorbidity (i.e., RR: top 2%, PHI: top 0.03%), indicating strong associa-
tions at molecular level. Indeed, our approach revealed that common mechanisms such as “GO: 0004993, serotonin 
receptor activity”, “GO: 0007202, activation of phospholipase C activity”, and “GO: 0008219, circadian rhythm” 
were associated with these comorbid diseases, explaining their common pathologies. In addition, “Diabetes mel-
litus” (i.e., ICD-9: 250) and “Ankylosing spondylitis and other inflammatory spondylopathies” (i.e., ICD-9: 720) 
also revealed high comorbidity29. These diseases have been reported to be highly co-occurred diseases in the Asian 
population30. However, the exact pathology underlying such comorbidity has not been reported yet. We found that 
they shared 40% of enriched GO terms including “GO: 0005141, interleukin-10 receptor binding”, “GO: 0050776, 
regulation of immune response”, and “GO: 0032868, response to insulin”. Interleukin-10 (IL-10) is known to be 
associated with ankylosing spondylitis31. Uncontrolled serum level of IL-10 is also closely related to diabetes31. 
These common biological functions could effectively explain the pathology of such comorbid diseases. In addition, 
“Unspecified myeloid leukemia” (i.e., ICD-9: 205.9) with “Other specified congenital anomalies of spinal cord” (i.e., 
ICD-9: 742.59), “Hypoglycemia” (i.e., ICD-9: 251.2) with “Essential hypertension” (i.e. ICD-9: 401.9), and “Anemia” 
(i.e. ICD-9: 285.9) with “Intermediate coronary syndrome” (i.e. ICD-9: 411.1) were also identified as associated 
disease pairs by sharing molecular functions to explain the common pathobiology (Supplementary Table 1).
Currently, a disease and its complications are usually handled based on their manifestations. However, if we 
understand the fact that such comorbid diseases might have co-occurred based on perturbation of shared patho-
logical mechanisms at molecular level, the therapy for such comorbid diseases can be changed. Instead of treating 
these comorbid diseases independently, we need to identify perturbed biological mechanisms that cause such 
diseases so that we can develop novel strategy for drug delivery and targeting.
Methods
Disease databases. We compiled the following four disease databases: OMIM32 (Online Mendelian 
Inheritance in Man, October 2014 version), HPO33 (Human Phenotype Ontology, October 2014 version), GAD34 
(Genetic Association Database, November 2013 version), and DO35 (Disease Ontology, October 2014 version). 
Since each disease database uses various sources including genomic data and literature data, we incorporated 
all four databases to extract extensive disease-gene associations. For example, the GAD database is collected 
genetic associations based on polymorphism data. The OMIM database is a well-known repository of dis-
ease-gene associations based on genetic information mostly limited to Mendelian disorders. Data in the HPO 
database are collected and annotated through medical literature and various experiment data. The DO database 
represents a comprehensive knowledge base of 8043 inherited developmental human diseases. It provides exten-
sive cross-mapping with MeSH (Medical Subject Headings), ICD (International Classification of Diseases), and 
OMIM identifiers. Diseases and genes in different databases are annotated with different identifiers. Since there is 
disease-identifier inconsistency among heterogeneous disease databases, an integration process for disease name 
normalization (Supplementary Fig. 4) was applied, covering a total of 1,439 associations among 1,022 diseases 
and 4,914 genes. The integration process is done though OMIM_ID. As shown in Supplementary Fig. 4, the HPO 
database provided the mapping information between HPO_ID and OMIM_ID. The DO database also provided 
the mapping information between DO_ID and OMIM_ID, and the GAD database also had mapping information 
between GAD_ID and OMIM_ID. Then, the mappings of OMIM_ID and ICD-9-CM codes were obtained from 
two sources. One was from previous studies11,12 mapped through manual curation. The other was from the DO 
database providing mapping between DO_ID and ICD-9-CM through OMIM_IDs.
US Medicare Data. The US Medicare is a national social insurance program, administered by the US federal 
government. It provides health insurance for age 65 and older people and maintains all history of health records 
for approximately 40 million people. In our study, we analyzed the US Medicare data of approximately 13,038,014 
individuals, who had the 32,341,347 inpatient hospital visits15. This data includes all diagnosis terms (e.g. ICD-9) 
which were clinically assigned to each of the patients.
Network databases. The STRING 9.1 network database16, one of the largest databases of direct 
protein-protein interactions and indirect functional interactions constructed from various data sources, was used. 
It contained 20,772 proteins with Ensembl protein identifiers with 2,425,315 interactions among them. Because 
our gene sets were represented by Entrez identifiers, Ensembl protein identifiers in the original STRING database 
were converted to Entrez identifiers by using mapping information in the STRING database. This resulted in 
18,074 genes with 2,153,757 interactions among them.
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Comorbidity score of a pair of diseases. Relative Risk (RR) and Phi-correlation (PHI) have been popu-
larly used7,12,15,19 to reflect the proportion of the number of patients that actually share diseases. We denoted that 
Cij was the number of patients who were diagnosed with both diseases i and j. The numbers of patients having 
disease i and j were Ii and Ij, respectively. N was the total number of patients. The relative risk of two diseases i and 
j were given by RPij/IPij, where RPij was the co-occurrence probability (i.e. Cij/N) of disease i and disease j. IPij was 
the joint probability of each of two diseases assuming they were independent (i.e. (Ii/N)*(Ij/N)). PHI, Pearson’s 
correlation for binary variables, was defined as ∗ − ∗ ∗ ∗ − ∗ −C I I I I N I N I( N )/( ( ) ( ) )ij i j i j i j . To quantita-
tively represent comorbid tendency between two diseases (d1, d2) in our study, we adapted the XD score measure18 
to represent the functional closeness of two disease-associated gene sets. The XD score was calculated as follows. 
In the first step, a score vector of a specific disease (d1) was created by setting 1 for all associated genes and 0 for 
all others. In the second step, the score vector was iteratively updated based on Random Walk with Restart (RWR) 
algorithm with a restart probability of p = 0.9 by using the STRING network database. In the third step, the XD 
score was calculated by using the updated score vector and associated genes of the other disease (d2). Genes in the 
updated score vector were sorted in descending order based on their association scores and discretized into 
equal-sized bins of the scores. The size and range of the bins were defined by the following equations:
=
−Bin size M m
number of bins (1)
∑=
−
⋅=
XD score P P
i n (2)i 1
n ic ia
∩= Target Genes Genes
Target Genes
P
(3)
c i
c
ic
=
∑ | |=
Genes
Genes
P
(4)
i
j
ia
j 1
n
where TargetGenesc and Genesi represented the set of genes associated with the current target disease (d2) and the 
set of genes in the ith bin respectively. Pic was the fraction of genes associated with the current target disease (d2) in 
the ith bin. Pia was the fraction of all genes in the ith bin. M and m were the maximum and minimum scores of the 
updated score vector respectively, n was the number of bins (in our study, n = 10 is used), and i was the current 
bin number. The reverse case (d2 was used for RWR) was also considered. The XD score was calculated using the 
same equations. The final XD score was defined as the minimum value of the two scores from d1 and d2 as the start 
of the RWR algorithm in order to represent reliable relatedness.
Estimating significance of correlation. We assessed the significance of observed correlation coefficient 
by comparing it to the set of correlation coefficients obtained from randomly permuted gene sets. The p-value 
for the Pearson’s correlation coefficient (PCC) between genetic variables including the XD score and comorbid 
tendency scores (i.e., RR and PHI-correlation) in Table 1 was estimated using the Monte Carlo sampling methods. 
We repeatedly permuted the values in the lists of each two variables and calculated PCCs. This was performed 
two million times to obtain the distribution of PCCs. The p-value was the fraction of total PCCs, which is larger 
than our correlation coefficient.
GO enrichment test for associated disease pairs. Gene Ontology (GO) enrichment analysis was per-
formed with each disease associated gene sets. GO terms enriched with one disease were identified with a hyper-
geometric test between a disease-associated gene set and GO-annotated gene sets with cutoff p-value of 0.05. 
After obtaining enriched GO terms for each disease, common GO terms were identified for each of comorbid 
disease pairs. They were used to explain common pathology for these comorbid diseases.
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